Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of innovative health solutions today announced that it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian influenza viruses (H5N1), specifically within the poultry industry.
The Company has engaged Vipragen Biosciences, an AAALAC-accredited preclinical Contract Research Organization (CRO) based in Mysuru, India ("Vipragen"), to conduct independent efficacy studies aimed at developing an antiviral solution for respiratory illnesses in humans. These studies are based on the Company's acquisition of patented respiratory illness prevention technology from IntraMont Technologies, Inc. ("IntraMont"). Phase I animal studies have already demonstrated significant efficacy in reducing lung viral load, and the compounds are now advancing into Phase II animal studies.
Mangoceuticals is leveraging this same technology to assess the feasibility of a drinking water-based application for poultry. The study is planned to focus on testing the efficacy of this solution when administered through drinking water and evaluating any necessary modifications to optimize its effectiveness in preventing avian flu infections among poultry populations.
Unlike traditional approaches that rely on synthetic vaccines or pharmaceutical treatments, Mangoceuticals' antiviral technology leverages Generally Recognized as Safe (GRAS) ingredients added to poultry drinking water. This method, we believe, may offer a simple, compliant, and non-pharmaceutical way to strengthen immune defenses in poultry. Following the Phase I animal studies, which concluded in late December, and pending promising results from the ongoing Phase II studies, though no assurances can be made, the Company believes this solution has the potential to be an effective tool in reducing the spread of H5N1 avian flu.
The ongoing avian flu outbreak has inflicted catastrophic losses on the poultry industry, leading to the culling of more than 148 million birds in the United States alone since 2022. These aggressive containment measures have crippled egg and poultry production, disrupted global supply chains, and sent consumer prices soaring. As of December 2024, the national average price of eggs hit $4.15 per dozen, with forecasts predicting an additional 20% increase in 2025.
In addition to direct losses from outbreaks, farms are extending significant amounts of resources on biosecurity measures and disease prevention strategies to protect flocks. Despite these costly efforts, avian flu remains a persistent threat, requiring a more effective and cost-efficient approach. Mangoceuticals' water-based antiviral technology aims to significantly reduce these expenses by hopefully providing a proactive, scalable, and easily deployable solution to help prevent infections before they spread.